1Hales B. Thalidomide on the comeback trail [J]. Nat Med, 1999, 5:489.
2Singhal S, Mehtu J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma[J]. N Engl J Med, 1999,341(21):1565.
3Raje N R, Anderson K. Thalidomide a revival story [J]. N Engl J Med, 1999, 341:1606.
4Teosk, Sabourin P J, O'Brien K, et al.Metabolism of thalidomide in human microsomes.cloned human cytochrome p-450isozymes.and Hansen' disease patients[J]. J Biochem Mol Toxicol, 2000, 14(3):140-147.
3[1]Singhal S,Mehta J,Desikan R,et al.Antitumor activity of thalidomide in refractory multiple myeloma[J].N Engl J Med,1999,341(21):1565-1571.
4[3]Rajkumar SV,Kyle RA.Angiogenesis in multiple myeloma[J].Semin On-col,2001,28(6):560-564.
5[4]Giovanni G.Michelle E,Letizia C,et al.Safety and efficiency of the thalindomide in patients with myeloid metaplasia[J].Br J Haematol,2001,114(4):78-83.
6[5]Mesa RA,Steensma DP,PardananiA,et al.A phase 2 trial of combination low-dase thalidomide and prednisone foe the treatment of myelofibrosis with myeloid melaplasia[J].Blood,2003,101(7):2534-2541.
7[7]Lisak L,Tahir S,Ahmed U,et al.Hematologic response to proteasome in-hibitor bortecomib in patients with myelodysplastic syndromes[J].Leuk Res,2003,27(suppl 1):S108.
8[8]Dimopoulos MA,Tsatalas C,Zomas A,et al.Treatment of Waldenstrom's mcroglobulinemia with single-agent thalidomide or with combination of clarithromycin,thalidomide and dexamelhasone[J].Semin Oncnl,2003,30(2):265-269.
9[10]Vogelsang GB,Farmer ER,Hess AD,et al.Thalidomide for thet reatment of chronict grofc-versus-host disease[J].N Engl J Med,1992,326(16):1055.
10[11]Koc S,Leisenring W,Flowers ME.Therapy for chronig grafc-ver-sus-host disease:a randomized trial comporing cyclosporine phls pred-nisone versus prednisone alone[J].Blood,2000,96(12):3995.
